Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Orientbio Inc. operates as a biotechnology company primarily engaged in the research, development, and commercialization of advanced biotechnological products and solutions. The company's core focus is on delivering cutting-edge innovations in life sciences, targeting diverse areas such as biomedical research, diagnostic applications, and therapeutic solutions. With its extensive expertise in genetic engineering and molecular biology, Orientbio Inc. plays a significant role in the pharmaceutical and healthcare industries by facilitating the development of essential medical breakthroughs. Furthermore, the company is involved in producing and supplying high-quality biological materials and services to research institutions and biopharma companies worldwide. Through its contributions, Orientbio Inc. is pivotal in advancing medical research, improving disease understanding, and supporting the creation of novel treatments. By harnessing the potentials of biotechnology, it remains an influential entity in the ongoing efforts to address global health challenges.
₩890.00
+₩15.00 (+1.71%)
Live · 11:09 AM
The business is unprofitable at the operating level (-13.89% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 1.2%, essentially flat. Margins also contracted 3.4pp. This is a business that needs a catalyst.
Operating margin contracted 3.4pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩29.75B
▲ +1.2% YoY
Net Income (TTM)
-₩4.57B
▲ +65.4% YoY
Op. Margin
-13.89%
▼ -3.4pp YoY
ROIC
-4.50%
▼ -1.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
₩546M
▲ +113.5% YoY
Op. Cash Flow (TTM)
₩2.59B
▲ +246.7% YoY
Net Debt
-₩30.84B
Net Cash Position
Cash & Equiv.
₩32.77B
3Y CAGR: +1.1%
3Y CAGR: -6.8%
Continue Research
Orientbio (002630.XKRX) trades around a two-stage DCF intrinsic value of about KRW 985.35 per share, so at KRW 890.00 the stock looks around fair value (10.7% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Orientbio scores 26/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about KRW 985.35 per share for 002630.XKRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around KRW 739.01. At today's KRW 890.00, that puts the stock about 10.7% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Orientbio scores 26 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -13.9% operating margin and a -4.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. 002630.XKRX currently trades around its estimated intrinsic value and scores 26/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.